Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
ACS Chemical Biology
|
December 27, 2014
Identification and further development of potent TBK1 inhibitors
André Richters, Debjit Basu, Julian Engel, et al.
European Journal of Haematology
|
May 7, 2021
Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX-based regimens in clinical routine
Noëlle Sieg, Jan-Hendrik Naendrup, Philipp Gödel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2012
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants
Johannes M Heuckmann, Hyatt Balke-Want, Florian Malchers, et al.
Blood Advances
|
July 11, 2025
Sequential BCMA CAR-T Cell Therapy in Refractory Multiple Myeloma
Tim Richardson, Udo Holtick, Jan Hendrik Frenking, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2011
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors
Johannes M Heuckmann, Michael Hölzel, Martin L Sos, et al.
European Journal of Haematology
|
January 28, 2022
Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high-grade B-cell lymphoma
Claus Moritz Graef, Philipp Gödel, Philipp Falderbaum, et al.
Molecular Cancer
|
June 26, 2023
Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
Hyatt Balke-Want, Vimal Keerthi, Nikolaos Gkitsas, et al.
European Journal of Haematology
|
February 19, 2024
Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR
Jan-Michel Heger, Yannick d'Hargues, Fanni Kleinert, et al.
Blood Advances
|
January 9, 2026
Zamtocabtagene Autoleucel in Relapsed/refractory B-NHL: 5-year Follow Up of a CD20/19 tandem CAR T Cell Phase 1 Trial
Hyatt Balke-Want, Philipp Gödel, Christoph Schmid, et al.
Blood
|
November 10, 2023
Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA
Jan-Michel Heger, Julia Mattlener, Jessica Schneider, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
ACS Chemical Biology
|
December 27, 2014
Identification and further development of potent TBK1 inhibitors
André Richters, Debjit Basu, Julian Engel, et al.
European Journal of Haematology
|
May 7, 2021
Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX-based regimens in clinical routine
Noëlle Sieg, Jan-Hendrik Naendrup, Philipp Gödel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2012
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants
Johannes M Heuckmann, Hyatt Balke-Want, Florian Malchers, et al.
Blood Advances
|
July 11, 2025
Sequential BCMA CAR-T Cell Therapy in Refractory Multiple Myeloma
Tim Richardson, Udo Holtick, Jan Hendrik Frenking, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2011
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors
Johannes M Heuckmann, Michael Hölzel, Martin L Sos, et al.
European Journal of Haematology
|
January 28, 2022
Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high-grade B-cell lymphoma
Claus Moritz Graef, Philipp Gödel, Philipp Falderbaum, et al.
Molecular Cancer
|
June 26, 2023
Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
Hyatt Balke-Want, Vimal Keerthi, Nikolaos Gkitsas, et al.
European Journal of Haematology
|
February 19, 2024
Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR
Jan-Michel Heger, Yannick d'Hargues, Fanni Kleinert, et al.
Blood Advances
|
January 9, 2026
Zamtocabtagene Autoleucel in Relapsed/refractory B-NHL: 5-year Follow Up of a CD20/19 tandem CAR T Cell Phase 1 Trial
Hyatt Balke-Want, Philipp Gödel, Christoph Schmid, et al.
Blood
|
November 10, 2023
Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA
Jan-Michel Heger, Julia Mattlener, Jessica Schneider, et al.
Page
of 2